Device Trial Radar · NCT03840395
The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
72
Actual
Start
Jun 17, 2019
Primary completion
Aug 1, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Phagenesis Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- NAMSA; Cytel Inc.
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-site, randomised, sham-controlled, single-blind (outcome assessor-blinded) study designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for the treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.
Conditions
- Dysphagia
Interventions
Pharyngeal Electrical Stimulation (PES)Device
The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of Phagenyx® treatment in reducing severity of unsafe swallows - Penetration-Aspiration Scale (PAS) ScoresTime frame: Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
- Effectiveness of Phagenyx® treatment in reducing the severity of unsafe swallows - Dysphagia Outcome and Severity Score (DOSS) scoreTime frame: 7±1 days after the final Phagenyx® treatment
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck - Medizinische Universität Innsbruck
Innsbruck, Austria
Medizinische Universität Innsbruck - Universitätsklinik für Anästhesie und Intensivmedizin
Innsbruck, Austria
Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin I
Innsbruck, Austria
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.